Company Description
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company.
The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases.
It focuses on developing traditional therapies and psychedelic treatments in formulations. The company’s lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.
It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief.
In addition, the company’s two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS).
The company’s research and development programs are conducted through collaborations with Columbia University, Medspray Pharma BV, and the University of Maryland, Baltimore.
The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020.
Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.
| Country | United States |
| Founded | 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Eric Weisblum |
Contact Details
Address: 677 North Washington Boulevard Sarasota, Florida 34236 United States | |
| Phone | 718 400 9031 |
| Website | silopharma.com |
Stock Details
| Ticker Symbol | SILO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001514183 |
| CUSIP Number | 82711P102 |
| ISIN Number | US82711P2011 |
| Employer ID | 46-2137136 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Eric Weisblum | Chairman, President and Chief Executive Officer |
| Daniel E. Ryweck | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 5, 2025 | 8-K | Current Report |
| Jul 29, 2025 | 8-K | Current Report |
| Jul 10, 2025 | 8-K | Current Report |
| Jul 3, 2025 | 8-K | Current Report |
| May 21, 2025 | SCHEDULE 13G | Filing |
| May 16, 2025 | 8-K | Current Report |
| May 16, 2025 | 424B4 | Prospectus |
| May 15, 2025 | EFFECT | Notice of Effectiveness |
| May 9, 2025 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| May 9, 2025 | 10-Q | Quarterly Report |